HighTower Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

HighTower Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,201	Closed	-$52K	–	1722
2014 Q3	$52K	Buy	1,201 +201	+20%	+$10.8K	﹤0.01%	1456
2014 Q2	$62K	Hold	1,000	–	–	﹤0.01%	1502
2014 Q1	$65K	Sell	1,000 -72	-7%	-$4.87K	﹤0.01%	1405
2013 Q4	$60K	Buy	1,072 +2	+0.2%	+$112	﹤0.01%	1410
2013 Q3	$66K	Sell	1,070 -2	-0.2%	-$135	﹤0.01%	1233
2013 Q2	$63K	Buy	+1,072	New	+$66K	﹤0.01%	1206

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HighTower Advisors's OREX Position: Q4 2014 in Review

HighTower Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2014, closing a stake of 1,201 shares — an estimated $52K sold.

HighTower Advisors first reported a position in OREX in Q2 2013 and held it in 6 quarters. The position peaked at $66K in Q3 2013. 147 funds tracked by Wall St. Rank hold OREX as of Q4 2014.

HighTower Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
HighTower Advisors sold 1,201 Orexigen Therapeutics, Inc. shares in Q4 2014, an estimated $52K.
HighTower Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
HighTower Advisors's Orexigen Therapeutics, Inc. position peaked at $66K in Q3 2013.
147 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2014.

Based on HighTower Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.